



O=C(O)C1=C(C#N)C2=C(C1)C(=O)C(C2)C3=CC4=C(C=C3)NCC4










































































































































* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 25 CA/CAPLUS - Russian Agency for Patents and Trademarks
 (ROSPATENT) added to list of core patent offices covered
NEWS 4 FEB 28 PATDPAFULL - New display fields provide for legal status
 data from INPADOC
NEWS 5 FEB 28 BABS - Current-awareness alerts (SDIs) available
NEWS 6 FEB 28 MEDLINE/LMEDLINE reloaded
NEWS 7 MAR 02 GBFULL: New full-text patent database on STN
NEWS 8 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS 9 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 10 MAR 22 KOREAPAT now updated monthly; patent information enhanced
NEWS 11 MAR 22 Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS 12 MAR 22 PATDPASPC - New patent database available
NEWS 13 MAR 22 REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS 14 APR 04 EPFULL enhanced with additional patent information and new
 fields
NEWS 15 APR 04 EMBASE - Database reloaded and enhanced
NEWS 16 APR 18 New CAS Information Use Policies available online
NEWS 17 APR 25 Patent searching, including current-awareness alerts (SDIs),
 based on application date in CA/CAPLUS and USPATFULL/USPAT2
 may be affected by a change in filing date for U.S.
 applications.
NEWS 18 APR 28 Improved searching of U.S. Patent Classifications for
 U.S. patent records in CA/CAPLUS

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
 MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
 AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:35:29 ON 10 MAY 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'REGISTRY' ENTERED AT 15:36:23 ON 10 MAY 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 MAY 2005 HIGHEST RN 850130-09-5
 DICTIONARY FILE UPDATES: 9 MAY 2005 HIGHEST RN 850130-09-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>


=>

L1 STRUCTURE UPLOADED


=> d 11

L1 HAS NO ANSWERS


L1 STR




Page 1-A



Page 1-B



Page 2-A



Page 2-B

NODE ATTRIBUTES:

HCOUNT	IS M1	AT	14
NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS R	AT	10
NSPEC	IS C	AT	11
NSPEC	IS C	AT	12
NSPEC	IS C	AT	13
NSPEC	IS C	AT	14
NSPEC	IS R	AT	15
NSPEC	IS R	AT	16
NSPEC	IS R	AT	17
NSPEC	IS C	AT	18
NSPEC	IS R	AT	19
NSPEC	IS R	AT	20
NSPEC	IS R	AT	21
NSPEC	IS R	AT	22
NSPEC	IS R	AT	23
NSPEC	IS R	AT	24
NSPEC	IS R	AT	25

NSPEC IS R AT 26
 NSPEC IS R AT 27
 NSPEC IS C AT 28
 NSPEC IS C AT 29
 DEFAULT MLEVEL IS ATOM
 MLEVEL IS CLASS AT 11 12 13 14 18 28 29
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 1 19
 NUMBER OF NODES IS 29

STEREO ATTRIBUTES: NONE

=> s l1
 SAMPLE SEARCH INITIATED 15:39:40 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 87 TO ITERATE

100.0% PROCESSED 87 ITERATIONS 2 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 1181 TO 2299
 PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 full
 THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 160.90 U.S. DOLLARS
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
 FULL SEARCH INITIATED 15:39:45 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 1987 TO ITERATE

100.0% PROCESSED 1987 ITERATIONS 23 ANSWERS
 SEARCH TIME: 00.00.01

L3 23 SEA SSS FUL L1

=> s l3 and hamanaka, e?/au
 NUMERIC VALUE NOT VALID 'HAMANAKA, E?'
 0 HAMANAKA, E?/AU
 L4 0 L3 AND HAMANAKA, E?/AU

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	168.51	168.93

FILE 'HCAPLUS' ENTERED AT 15:40:40 ON 10 MAY 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 May 2005 VOL 142 ISS 20
FILE LAST UPDATED: 9 May 2005 (20050509/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l3 and hamanaka, e?/au
      13 L3
      63 HAMANAKA, E?/AU
L5      0 L3 AND HAMANAKA, E?/AU
```

```
=> s l3 and angel, g?/au
      13 L3
      107 ANGEL, G?/AU
L6      0 L3 AND ANGEL, G?/AU
```

```
=> s l3 and mularski, c?/au
      13 L3
      10 MULARSKI, C?/AU
L7      0 L3 AND MULARSKI, C?/AU
```

```
=> s l3 and ruggeri, r?/au
      13 L3
      141 RUGGERI, R?/AU
L8      0 L3 AND RUGGERI, R?/AU
```

```
=> s l3 and wester, r?/au
      13 L3
      294 WESTER, R?/AU
L9      0 L3 AND WESTER, R?/AU
```

```
=> s l3
L10      13 L3
```

```
=> d l10, ibib abs hitstr, 11-13
```

L10 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN


Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER:	2000:366036 HCAPLUS
DOCUMENT NUMBER:	133:4646
TITLE:	Crystal modification A of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
INVENTOR(S):	Himmeler, Thomas; Hallenbach, Werner; Rast, Hubert
PATENT ASSIGNEE(S):	Bayer A.-G., Germany
SOURCE:	Ger. Offen., 8 pp. CODEN: GWXXBX
DOCUMENT TYPE:	Patent
LANGUAGE:	German
FAMILY ACC. NUM. COUNT:	1
<u>PATENT INFORMATION:</u>	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>DE 19854356</u>	A1	20000531	<u>DE 1998-19854356</u>	19981125
<u>CA 2351712</u>	AA	20000602	<u>CA 1999-2351712</u>	19991115
<u>WO 2000031075</u>	A1	20000602	<u>WO 1999-EP8775</u>	19991115
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
<u>BR 9915669</u>	A	20010814	<u>BR 1999-15669</u>	19991115
<u>EP 1133496</u>	A1	20010919	<u>EP 1999-958040</u>	19991115
<u>EP 1133496</u>	B1	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
<u>TR 200101438</u>	T2	20011022	<u>TR 2001-200101438</u>	19991115
<u>JP 2002530406</u>	T2	20020917	<u>JP 2000-583903</u>	19991115
<u>NZ 511861</u>	A	20021220	<u>NZ 1999-511861</u>	19991115
<u>AU 763883</u>	B2	20030731	<u>AU 2000-15533</u>	19991115
<u>CN 1135229</u>	B	20040121	<u>CN 1999-813686</u>	19991115
<u>TW 576835</u>	B	20040221	<u>TW 1999-88119810</u>	19991115
<u>AT 264858</u>	E	20040515	<u>AT 1999-958040</u>	19991115
<u>PT 1133496</u>	T	20040831	<u>PT 1999-958040</u>	19991115
<u>ES 2217843</u>	T3	20041101	<u>ES 1999-958040</u>	19991115
<u>RU 2247122</u>	C2	20050227	<u>RU 2001-117525</u>	19991115
<u>NO 2001002460</u>	A	20010518	<u>NO 2001-2460</u>	20010518
<u>US 6436955</u>	B1	20020820	<u>US 2001-856669</u>	20010523
<u>HK 1042703</u>	A1	20041203	<u>HK 2002-104444</u>	20020613
PRIORITY APPLN. INFO.:			<u>DE 1998-19854356</u>	A 19981125
			<u>WO 1999-EP8775</u>	W 19991115

GI

NO



AB The title compd. in crystal modification A (I), useful as a medical and veterinary bactericide, is stable during extended storage without conversion to the amorphous form or any other crystal modification, and is less hygroscopic than the amorphous form of the compd. I is produced by dissolving the amorphous compd. or an unknown modification of it in hot water or a hot water-alc. mixt., adding an alc. (esp. EtOH or iso-PrOH), and cooling to room temp. I (m. 249-252°) is characterized by its powder x-ray diffractogram, differential thermogram, and IR spectrum.

IT 195532-12-8P


RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)

(crystal modification A of cyanocyclopropyl(diazabicyclononyl)fluorodihydrooxoquinolinecarboxylic acid)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full
Text

Citing
References

ACCESSION NUMBER: 2000:366035 HCAPLUS

DOCUMENT NUMBER: 133:4645

TITLE: Crystal modification B of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

INVENTOR(S): Himmeler, Thomas; Hallenbach, Werner; Rast, Hubert

PATENT ASSIGNEE(S): Bayer A.-G., Germany

SOURCE: Ger. Offen., 8 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>DE 19854355</u>	A1	20000531	<u>DE 1998-19854355</u>	19981125
<u>CA 2351707</u>	AA	20000602	<u>CA 1999-2351707</u>	19991115
<u>WO 2000031076</u>	A1	20000602	<u>WO 1999-EP8776</u>	19991115
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
<u>BR 9915682</u>	A	20010814	<u>BR 1999-15682</u>	19991115
<u>EP 1133497</u>	A1	20010919	<u>EP 1999-959278</u>	19991115
<u>EP 1133497</u>	B1	20050223		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
<u>TR 200101444</u>	T2	20020121	<u>TR 2001-200101444</u>	19991115
<u>JP 2002530407</u>	T2	20020917	<u>JP 2000-583904</u>	19991115
<u>NZ 511862</u>	A	20030829	<u>NZ 1999-511862</u>	19991115
<u>AU 767890</u>	B2	20031127	<u>AU 2000-16517</u>	19991115

AT 289606	E	20050315	AT 1999-959278	19991115
RU 2248355	C2	20050320	RU 2001-117521	19991115
NO 2001002461	A	20010518	NO 2001-2461	20010518
US 6664268	B1	20031216	US 2001-856670	20010523
HK 1042705	A1	20050311	HK 2002-104458	20020614
PRIORITY APPLN. INFO.:			DE 1998-19854355	A 19981125
OTHER SOURCE(S):			WO 1999-EP8776	W 19991115
GI				
CASREACT 133:4645				



AB The title compd. in crystal modification B (I), useful as a medical and veterinary bactericide, is stable during extended storage without conversion to the amorphous form or any other crystal modification, and is less hygroscopic than the amorphous form of the compd. I is produced either (a) by reaction of 7-halo-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid with (1S,6S)-2,8-diazabicyclo[4.3.0]nonane in the presence of a base in a mixt. of EtOH and a polar aprotic diluent such as N-methylpyrrolidone, DMF, or sulfolane, or (b) by heating an unknown modification of the compd. in the presence of a base in EtOH, n-PrOH, iso-PrOH, or a mixt. of one of these alcs. with one of the polar aprotic diluents named previously. I (m. 243-245°) is characterized by its powder x-ray diffractogram, differential thermogram, and IR spectrum.


IT **195532-12-8P**

RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(crystal modification B of cyanocyclopropyl(diazabicyclononyl)fluorodihydrooxoquinolinecarboxylic acid)

RN **195532-12-8** HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN


Full Text References

ACCESSION NUMBER: 1997:579724 HCAPLUS

DOCUMENT NUMBER: 127:248093
 TITLE: 8-Cyano-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid derivatives
 INVENTOR(S): Bartel, Stefan; Jaetsch, Thomas; Himmeler, Thomas; Rast, Hans-Georg; Hallenbach, Werner; Heinen, Ernst; Pirro, Franz; Scheer, Martin; Stegemann, Michael; Stupp, Hans-Peter; Wetzstein, Heinz-Georg
 PATENT ASSIGNEE(S): Bayer A.-G., Germany; Bartel, Stefan; Jaetsch, Thomas; Himmeler, Thomas; Rast, Hans-Georg; Hallenbach, Werner; Heinen, Ernst; Pirro, Franz; Scheer, Martin; et al.
 SOURCE: PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 9731001</u>	A1	19970828	<u>WO 1997-EP637</u>	19970212
W: AU, BB, BG, BR, BY, CA, CN, CZ, HU, IL, JP, KR, KZ, LK, MX, NO, NZ, PL, RO, RU, SK, TR, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
<u>DE 19633805</u>	A1	19970828	<u>DE 1996-19633805</u>	19960822
<u>ZA 9701507</u>	A	19970916	<u>ZA 1997-1507</u>	19970202
<u>CA 2247020</u>	AA	19970828	<u>CA 1997-2247020</u>	19970212
<u>AU 9717689</u>	A1	19970910	<u>AU 1997-17689</u>	19970212
<u>AU 715341</u>	B2	20000120		
<u>EP 882049</u>	A1	19981209	<u>EP 1997-903260</u>	19970212
<u>EP 882049</u>	B1	20021120		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
<u>CN 1211984</u>	A	19990324	<u>CN 1997-192523</u>	19970212
<u>CN 1073112</u>	B	20011017		
<u>BR 9707606</u>	A	19990727	<u>BR 1997-7606</u>	19970212
<u>NZ 331468</u>	A	20000228	<u>NZ 1997-331468</u>	19970212
<u>JP 2000504734</u>	T2	20000418	<u>JP 1997-529755</u>	19970212
<u>IL 125444</u>	A1	20010319	<u>IL 1997-125444</u>	19970212
<u>RU 2173318</u>	C2	20010910	<u>RU 1998-117814</u>	19970212
<u>EP 1215202</u>	A1	20020619	<u>EP 2002-6519</u>	19970212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
<u>AT 228130</u>	E	20021215	<u>AT 1997-903260</u>	19970212
<u>CZ 291251</u>	B6	20030115	<u>CZ 1998-2684</u>	19970212
<u>ES 2184060</u>	T3	20030401	<u>ES 1997-903260</u>	19970212
<u>PT 882049</u>	T	20030430	<u>PT 1997-903260</u>	19970212
<u>PL 186737</u>	B1	20040227	<u>PL 1997-328577</u>	19970212
<u>TW 390879</u>	B	20000521	<u>TW 1997-86101994</u>	19970220
<u>US 6323213</u>	B1	20011127	<u>US 1998-125191</u>	19980813
<u>NO 9803819</u>	A	19980820	<u>NO 1998-3819</u>	19980820
<u>NO 311521</u>	B1	20011203		
<u>HK 1018903</u>	A1	20020510	<u>HK 1999-104030</u>	19990917
<u>US 6278013</u>	B1	20010821	<u>US 2000-718062</u>	20001121
<u>CN 1335301</u>	A	20020213	<u>CN 2001-110855</u>	20010228
PRIORITY APPLN. INFO.:			<u>DE 1996-19606762</u>	A 19960223
			<u>DE 1996-19633805</u>	A 19960822
			<u>EP 1997-903260</u>	A3 19970212
			<u>WO 1997-EP637</u>	W 19970212
			<u>US 1998-125191</u>	A3 19980813
OTHER SOURCE(S):	MARPAT	127:248093		

GI



AB Title compds. I [R1 = H, alkyl, optionally substituted by OH, OMe, NH2, NHMe, NMe2, or (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl; R2 = H, benzyl, alkyl, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, CH=CHCO2R3, CH2CH2CO2R3, CH2CH2CN, CH2CH2COMe, CH2COMe; R3 = Me, Et, R4(NHCHR5CO)n; R4 = H, alkyl, CO2CMe3; R5 = H, alkyl, hydroxyalkyl, aminoalkyl, thioalkyl, carboxyalkyl, benzyl; n = 1, 2; Y = O, S] were prepd. for use as antibacterial agents. Thus, I [R1 = OH, R2 = H, Y = O] was prepd. by aminating the 7-chloroquinoline. I [R1 = OH, R2 = H, Y = O] had min. inhibitory concns. against a no. of bacteria that were superior to those of enrofloxacin.

IT 195532-12-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of diazabicyclononylquinolinecarboxylic acid derivs. as bactericides)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Not seen by druck

IT 195532-14-0P 195532-16-2P 195532-18-4P

195532-20-8P 195532-22-0P 195532-25-3P

195532-27-5P 195532-29-7P 195532-31-1P

195532-33-3P 195532-36-6P 195532-39-9P

195532-42-4P 195532-45-7P 195532-48-0P

195532-58-2P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of diazabicyclononylquinolinecarboxylic acid derivs. as bactericides)

RN 195532-14-0 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-16-2 HCAPLUS


CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 195532-12-8

CMF C21 H21 F N4 O3


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 195532-18-4 HCAPLUS


CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 195532-12-8

CMF C21 H21 F N4 O3


Absolute stereochemistry.



CM 2

CRN 104-15-4

CMF C7 H8 O3 S

RN 195532-20-8 HCAPLUS


CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 195532-12-8

CMF C21 H21 F N4 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2

RN 195532-22-0 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-7-[1-(3-ethoxy-3-oxo-1-propenyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-6-fluoro-1,4-dihydro-4-oxo-, [4aS-[1(E),4α,7α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 195532-25-3 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[octahydro-1-[(5-methyl-2-oxo-1,3-dioxolan-4-yl)methyl]-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, [4aS-(4aα,7aα)]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-27-5 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[octahydro-1-(3-oxobutyl)-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-29-7 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-7-[1-(2-cyanoethyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-31-1 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[octahydro-1-(2-oxopropyl)-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-33-3 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-7-[1-(3-ethoxy-3-oxopropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-6-fluoro-1,4-dihydro-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-36-6 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-1-oxopropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-39-9 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-1-oxopropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(S*),4aα,7aα]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-42-4 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-3-methyl-1-oxobutyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-45-7 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-1-oxo-3-phenylpropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-48-0 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-4-methyl-1-oxopentyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-58-2 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monosodium salt, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 15:35:29 ON 10 MAY 2005)

FILE 'REGISTRY' ENTERED AT 15:36:23 ON 10 MAY 2005

L1 STRUCTURE UPLOADED
L2 2 S L1
L3 23 S L1 FULL
L4 0 S L3 AND HAMANAKA, E?/AU

FILE 'HCAPLUS' ENTERED AT 15:40:40 ON 10 MAY 2005

L5 0 S L3 AND HAMANAKA, E?/AU
L6 0 S L3 AND ANGEL, G?/AU
L7 0 S L3 AND MULARSKI, C?/AU
L8 0 S L3 AND RUGGERI, R?/AU
L9 0 S L3 AND WESTER, R?/AU
L10 13 S L3

=> d l10, ibib abs hitstr, 1-13

L10 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text Citing References

ACCESSION NUMBER: 2005:177894 HCAPLUS
DOCUMENT NUMBER: 142:254561
TITLE: Use of quinolone antibiotics for controlling bacterial diseases of the oral cavity
INVENTOR(S): Daube, Gert; Edingloh, Markus; Stephan, Bernd; Pirro, Franz; Limet, Agnes
PATENT ASSIGNEE(S): Bayer Healthcare AG, Germany
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005018641	A2	20050303	WO 2004-EP8629	20040802
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

DE 10337191 A1 20050317 DE 2003-10337191 20030813

PRIORITY APPLN. INFO.: DE 2003-10337191 A 20030813

AB The invention relates to the use of certain quinolone antibiotics for controlling bacterial diseases of the oral cavity, esp. in veterinary medicine.

IT 195532-12-8, Pradofloxacin


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(quinolone antibiotic for control of bacterial disease of oral cavity)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-
[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full-
Text

Chem
References

ACCESSION NUMBER: 2004:800774 HCAPLUS
DOCUMENT NUMBER: 141:282840
TITLE: Controlled-release drug delivery system containing
saccharose acetate isobutyrate (SAIB)
INVENTOR(S): Fraatz, Kristine; Mertin, Dirk; Heep, Iris
PATENT ASSIGNEE(S): Bayer Healthcare AG, Germany
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10312346	A1	20040930	DE 2003-10312346	20030320
WO 2004082658	A1	20040930	WO 2004-EP2318	20040306

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: DE 2003-10312346 A 20030320


AB The invention concerns controlled-release drug delivery systems that include (a) a drug; (b) saccharose acetate isobutyrate (SAIB); (c) glycerininformal, isopropylidene glycerol or their mixt. as solvent. A cosolvent can be added; they are selected from the group of ethanol, n-butanol and benzyl alc. Thus a formulation contained (wt./wt.%): SAIB 40; pradofloxacin 3; n-butanol 3; ethanol 5; 1N HCl 1.7; glycerininformal to 100.

IT 195532-12-8, Pradofloxacin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled release drug delivery system contg. saccharose acetate isobutyrate (SAIB))

RN 195532-12-8 HCAPLUS
 CN 3-Quinolonecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-
 [(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full
Text

ACCESSION NUMBER: 2003:971863 HCAPLUS
 DOCUMENT NUMBER: 140:31484
 TITLE: Pharmaceutical preparations, especially quinolone antibiotics, for oral administration, containing ion-exchange resins loaded with active ingredients and intrinsically viscous gelling agents as thickening agents
 INVENTOR(S): Mertin, Dirk; Edingloh, Markus; Daube, Gert
 PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany; Bayer Healthcare AG
 SOURCE: PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101422	A2	20031211	WO 2003-EP5228	20030519
WO 2003101422	A3	20041209		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10224086	A1	20031211	DE 2002-10224086	20020531
BR 2003011511	A	20050222	BR 2003-11511	20030519
EP 1513500	A2	20050316	EP 2003-755931	20030519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:				
			DE 2002-10224086	A 20020531
			WO 2003-EP5228	W 20030519

AB The invention relates to pharmaceutical prepns. for oral administration, said prepns. contg. at least one active ingredient which is bound to an

ion exchanger. The inventive preps. also contain an intrinsically viscous gelling agent as a thickening agent in order to improve their phys. stability and acceptance, esp. by animals. Thus 0.18 kg methyl-p-hydroxybenzoate and 0.02 kg propyl-p-hydroxybenzoate were dissolved in 75.0 kg hot water; 0.3 kg Xanthan gum and 0.3 kg bentonite were added under vigorous mixing; mixing was continued for one hour at 70°C. The mixt. was cooled; 6.0 kg pradofloxacin, 18.0 kg Amberlite IRP 64 and 1.0 kg vanillin were added to the sol.

IT 195532-12-8, Pradofloxacin


RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(pharmaceutical preps., esp. quinolone antibiotics, for oral administration, contg. ion-exchange resins loaded with active ingredients and intrinsically viscous gelling agents as thickening agents)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full
Text

References

ACCESSION NUMBER: 2003:744337 HCAPLUS
DOCUMENT NUMBER: 139:301379
TITLE: Clinical efficacy and safety of pradofloxacin in the treatment of canine pyoderma and wound infections under field conditions
AUTHOR(S): Stephan, B.; Hellmann, K.; Liege, P.; Granier, S.; Knoppe, T. N.; Heinen, E.; Greife, H. A.
CORPORATE SOURCE: Animal Health Business Group, Bayer AG, Leverkusen, Germany
SOURCE: Journal of Veterinary Pharmacology and Therapeutics (2003), 26(Suppl. 1), 217-218
CODEN: JVPTD9; ISSN: 0140-7783
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Pradofloxacin is a novel 8-cyanofluoroquinolone with improved in vitro activity against a wide range of pathogenic bacteria. Tablets of different strengths are currently developed for the treatment of bacterial infections in dogs and cats. The objective of this work was to assess the clin. efficacy and safety of pradofloxacin in the treatment of canine pyoderma and wound infections.

IT 195532-12-8, Pradofloxacin


RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological

activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (clin. efficacy and safety of pradofloxacin in treatment of canine
 pyoderma and wound infections under field conditions)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-
 [(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full
Text

Citing
References

ACCESSION NUMBER: 2003:744304 HCAPLUS
 DOCUMENT NUMBER: 140:331682
 TITLE: Analytical method for the determination of
 pradofloxacin in serum and urine by turbulent flow
 chromatography/tandem mass spectrometry
 AUTHOR(S): Krebber, R.
 CORPORATE SOURCE: Bayer CropScience AG, BCS-D-ROCS, Monheim, Germany
 SOURCE: Journal of Veterinary Pharmacology and Therapeutics
 (2003), 26(Suppl. 1), 102-103
 CODEN: JVPTD9; ISSN: 0140-7783
 PUBLISHER: Blackwell Publishing Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A high-throughput anal. method was developed and validated for the detn.
 of pradofloxacin (PRA) concns. in body fluids. A turbulent flow
 chromatog. system 2300 HTLC with auto injector CTC HTS PAL coupled to a
 tandem mass spectrometer Sciex API 365 was used. Serum and urine samples
 of dogs and cats were analyzed within a mean accuracy between -1 and 4%
 and a precision between 5.1 and 7.8%. The method enables direct anal. of
 PRA in several body fluids. It combines a min. of sample prepn. with fast
 and highly selective detn. within an extremely wide range of linearity and
 is therefore highly suitable to assess PRA concns. in pharmacokinetic
 studies.


IT 195532-12-8, Pradofloxacin

RL: ANT (Analyte); ANST (Analytical study)
 (anal. method for detn. of pradofloxacin in serum and urine by
 turbulent flow chromatog./tandem mass spectrometry in cats and dogs)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-
 [(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text Links
References


ACCESSION NUMBER: 2003:744303 HCAPLUS
DOCUMENT NUMBER: 140:331734
TITLE: Protein binding of pradofloxacin, a novel 8-cyanofluoroquinolone, in dog and cat plasma
AUTHOR(S): Bregante, M. A.; De Jong, A.; Calvo, A.; Hernandez, E.; Rey, R.; Garcia, M. A.
CORPORATE SOURCE: Veterinary Faculty of University of Zaragoza, Zaragoza, Spain
SOURCE: Journal of Veterinary Pharmacology and Therapeutics (2003), 26(Suppl. 1), 87-88
CODEN: JVPTD9; ISSN: 0140-7783
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The in vitro protein binding of pradofloxacin (PRA) in plasma of dogs and cats was investigated. Enrofloxacin (ENR), the first veterinary fluoroquinolone, was tested as a ref. drug. For concns. of 0.15, 0.75 and 1.50 µg/mL, the percentages of free unbound drug in dog plasma were 63.4±14.8, 63.6±10.5 and 64.2±8.8 for PRA and 59.7±13.3, 54.3±7.3 and 68.4±5.0 for ENR, resp. In cat plasma, the percentages unbound drug were 68.6±7.8, 70.4±11.5, and 71.2±6.2 for PRA and 63.7±10.5, 66.0±9.8 and 73.4±12.5 for ENR. The plasma protein binding of PRA amounted to 29-37% over a ten-fold concn. range: similar findings for ENR (27-46% bound) are in agreement with previous results. A concn. dependency was absent for PRA, but in case of ENR there were statistically significant differences both in dogs and cats; the numerical differences, however, were small.

IT 195532-12-8, Pradofloxacin
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(protein binding of pradofloxacin, novel 8-cyanofluoroquinolone, in dog and cat plasma)

RN 195532-12-8 HCAPLUS
CN 3-Quinolonecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 2003:76654 HCAPLUS
DOCUMENT NUMBER: 138:126984
TITLE: Pharmaceutical preparations for oral administration
containing ion exchange resins loaded with active
ingredients
INVENTOR(S): Mertin, Dirk; Block, Wolfgang; Hamann, Hans-juergen
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2003007995</u>	A2	20030130	<u>WO 2002-EP7417</u>	20020704
<u>WO 2003007995</u>	A3	20030731		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
<u>DE 10134719</u>	A1	20030206	<u>DE 2001-10134719</u>	20010717
<u>CA 2453616</u>	AA	20030130	<u>CA 2002-2453616</u>	20020704
<u>EP 1411894</u>	A2	20040428	<u>EP 2002-743262</u>	20020704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
<u>BR 2002011149</u>	A	20040629	<u>BR 2002-11149</u>	20020704
<u>JP 2005500332</u>	T2	20050106	<u>JP 2003-513600</u>	20020704
<u>US 2004247560</u>	A1	20041209	<u>US 2004-483635</u>	20040721
<u>PRIORITY APPLN. INFO.:</u>				
			<u>DE 2001-10134719</u>	A 20010717
			<u>WO 2002-EP7417</u>	W 20020704

AB The invention relates to pharmaceutical prepn. contg. at least one active ingredient which is linked to an ion exchanger. In order to improve the palatability and to increase the stability, at least 90 % of said active ingredient/ion exchanger particles are smaller than 50 μ m. Quinolone antibiotics are bound to cation exchange resins, esp. for the prepn. cat medication. Thus 3.86 kg enrofloxacin and 19.24 kg Amberlite IRP64 were

suspended in 76.90 kg purified water and stirred for at least 8 h at room temp. The suspension was transferred to a filter dryer, filtered and dried at 85°C. The obtained 17.96 kg of enrofloxacin-loaded resin was suspended with 60 g colloidal silica, 100.30 kg neutral oil (e.g. Miglyol 812) and ground in a perl mill; at least 90% of the particles were smaller than 10 µm.


IT 195532-12-8

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical preps. for oral administration contg. ion exchange resins loaded with active ingredients)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN


Full
Text

Chemical
References

ACCESSION NUMBER: 2000:607382 HCAPLUS
DOCUMENT NUMBER: 133:213147
TITLE: Crystal modification C of 8-cyano-1-cyclopropyl-7-[(1S,6S)-2,8-diazabicyclo[4.3.0]nonan-8-yl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
INVENTOR(S): Rast, Hubert; Himmler, Thomas
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19908449	A1	20000831	DE 1999-19908449	19990226
CA 2362801	AA	20000908	CA 2000-2362801	20000214
WO 2000052009	A1	20000908	WO 2000-EP1202	20000214
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
NZ 513750	A	20010928	NZ 2000-513750	20000214

<u>EP 1155018</u>	A1	20011121	<u>EP 2000-909166</u>	20000214
<u>EP 1155018</u>	B1	20021030		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
<u>BR 2000008493</u>	A	20020205	<u>BR 2000-8493</u>	20000214
<u>TR 200102434</u>	T2	20020321	<u>TR 2001-200102434</u>	20000214
<u>JP 2002538158</u>	T2	20021112	<u>JP 2000-602235</u>	20000214
<u>AT 226952</u>	E	20021115	<u>AT 2000-909166</u>	20000214
<u>PT 1155018</u>	T	20030228	<u>PT 2000-909166</u>	20000214
<u>ES 2181644</u>	T3	20030301	<u>ES 2000-909166</u>	20000214
<u>AU 763003</u>	B2	20030710	<u>AU 2000-31543</u>	20000214
<u>RU 2248356</u>	C2	20050320	<u>RU 2001-126300</u>	20000214
<u>ZA 2001006289</u>	A	20020731	<u>ZA 2001-6289</u>	20010731
<u>NO 2001004061</u>	A	20010821	<u>NO 2001-4061</u>	20010821
<u>US 6649762</u>	B1	20031118	<u>US 2001-914090</u>	20010822
<u>PRIORITY APPLN. INFO.:</u>			<u>DE 1999-19908449</u>	A 19990226
GI			<u>WO 2000-EP1202</u>	W 20000214



AB The title compd. (I) is converted to stable crystal modification C (m. 235-237°) by holding I at room temp. and relative humidity ≥92% until no further wt. gain occurs, drying, and heating to above the conversion temp. (150-180°). I modification D is characterized by its powder x-ray diffractogram, IR spectrum, and by DTA. I is highly active against pathogenic bacteria in human and veterinary medicine.


IT 195532-12-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(crystal modification D of cyanocyclopropyl(diazabicyclononyl)fluorodihydrooxoquinolinecarboxylic acid)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN


Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 2000:607381 HCAPLUS
 DOCUMENT NUMBER: 133:213146
 TITLE: Crystal modification D of 8-cyano-1-cyclopropyl-7-
 [(1S,6S)-2,8-diazabicyclo[4.3.0]nonan-8-yl]-6-fluoro-
 1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
 INVENTOR(S): Himmeler, Thomas; Rast, Hubert
 PATENT ASSIGNEE(S): Bayer A.-G., Germany
 SOURCE: Ger. Offen., 12 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>DE 19908448</u>	A1	20000831	<u>DE 1999-19908448</u>	19990226
<u>CA 2362804</u>	AA	20000908	<u>CA 2000-2362804</u>	20000214
<u>WO 2000052010</u>	A1	20000908	<u>WO 2000-EP1203</u>	20000214
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
<u>EP 1159277</u>	A1	20011205	<u>EP 2000-909167</u>	20000214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
<u>BR 2000008520</u>	A	20011218	<u>BR 2000-8520</u>	20000214
<u>TR 200102435</u>	T2	20020121	<u>TR 2001-200102435</u>	20000214
<u>JP 2002538159</u>	T2	20021112	<u>JP 2000-602236</u>	20000214
<u>AU 760710</u>	B2	20030522	<u>AU 2000-31544</u>	20000214
<u>AU 2000031544</u>	A5	20000921		
<u>NZ 513749</u>	A	20031031	<u>NZ 2000-513749</u>	20000214
<u>RU 2248357</u>	C2	20050320	<u>RU 2001-126301</u>	20000214
<u>ZA 2001006050</u>	A	20020724	<u>ZA 2001-6050</u>	20010724
<u>NO 2001004059</u>	A	20010821	<u>NO 2001-4059</u>	20010821
<u>US 6492391</u>	B1	20021210	<u>US 2001-914031</u>	20010822
PRIORITY APPLN. INFO.:			<u>DE 1999-19908448</u>	A 19990226
			<u>WO 2000-EP1203</u>	W 20000214

GI

40



AB The title compd. (I) is converted to stable crystal modification D (m.
 261-265°) by dissolving I in H₂O to a concn. of 1-3 wt.%, allowing
 the soln. to stand until a ppt. forms, removing the ppt. by filtration,

drying the remaining soln., and heating the solid obtained to above the transition temp. (130-160°). I modification D is characterized by its powder x-ray diffractogram, IR spectrum, and by DTA. I is highly active against pathogenic bacteria in human and veterinary medicine.

IT 195532-12-8


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(crystal modification D of cyanocyclopropyl(diazabicyclononyl)fluorodihydrooxoquinolinecarboxylic acid)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full-
Text

Chemical
References

ACCESSION NUMBER: 2000:366037 HCAPLUS
DOCUMENT NUMBER: 133:4647
TITLE: Semihydrochloride of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
INVENTOR(S): Himmeler, Thomas; Rast, Hubert
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 16 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19854357	A1	20000531	DE 1998-19854357	19981125
CA 2351714	AA	20000602	CA 1999-2351714	19991115
WO 2000031077	A1	20000602	WO 1999-EP8778	19991115
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 9915684	A	20010814	BR 1999-15684	19991115

<u>EP 1133495</u>	A1	20010919	<u>EP 1999-955995</u>	19991115
<u>EP 1133495</u>	B1	20021009		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
<u>TR 200101443</u>	T2	20010921	<u>TR 2001-200101443</u>	19991115
<u>JP 2002530408</u>	T2	20020917	<u>JP 2000-583905</u>	19991115
<u>AT 225790</u>	E	20021015	<u>AT 1999-955995</u>	19991115
<u>ES 2181488</u>	T3	20030216	<u>ES 1999-955995</u>	19991115
<u>PT 1133495</u>	T	20030228	<u>PT 1999-955995</u>	19991115
<u>AU 759769</u>	B2	20030501	<u>AU 2000-12716</u>	19991115
<u>NZ 511863</u>	A	20030530	<u>NZ 1999-511863</u>	19991115
<u>RU 2242475</u>	C2	20041220	<u>RU 2001-117528</u>	19991115
<u>NO 2001002532</u>	A	20010702	<u>NO 2001-2532</u>	20010523

PRIORITY APPLN. INFO.:OTHER SOURCE(S):
GI

CASREACT 133:4647

<u>DE 1998-19854357</u>	A	19981125
<u>WO 1999-EP8778</u>	W	19991115



AB The title compd. (I), useful as a medical and veterinary bactericide, shows good water soly. (19 wt.%). I is produced by reaction of 7-halo-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid with (1S,6S)-2,8-diazabicyclo[4.3.0]nonane in the presence of a base in one of the following diluents: (a) a C₂4 aliph. alc., (b) a mixt. of a C₃ alc. with the polar aprotic diluent, N-methylpyrrolidone; (c) a mixt. of n-ProH with DMF. I (m. 278-280°) is characterized by its powder x-ray diffractogram, differential thermogram, and IR spectrum.


IT 271252-05-2P

RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(semihydrochloride of cyanocyclopropyl(diazabicyclononyl)fluorodihydroxyquinolinecarboxylic acid)

RN 271252-05-2 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride (2:1) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full
Text


Citing
References

ACCESSION NUMBER: 2000:366036 HCAPLUS
DOCUMENT NUMBER: 133:4646
TITLE: Crystal modification A of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
INVENTOR(S): Himmeler, Thomas; Hallenbach, Werner; Rast, Hubert
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>DE 19854356</u>	A1	20000531	<u>DE 1998-19854356</u>	19981125
<u>CA 2351712</u>	AA	20000602	<u>CA 1999-2351712</u>	19991115
<u>WO 2000031075</u>	A1	20000602	<u>WO 1999-EP8775</u>	19991115
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
<u>BR 9915669</u>	A	20010814	<u>BR 1999-15669</u>	19991115
<u>EP 1133496</u>	A1	20010919	<u>EP 1999-958040</u>	19991115
<u>EP 1133496</u>	B1	20040421		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
<u>TR 200101438</u>	T2	20011022	<u>TR 2001-200101438</u>	19991115
<u>JP 2002530406</u>	T2	20020917	<u>JP 2000-583903</u>	19991115
<u>NZ 511861</u>	A	20021220	<u>NZ 1999-511861</u>	19991115
<u>AU 763883</u>	B2	20030731	<u>AU 2000-15533</u>	19991115
<u>CN 1135229</u>	B	20040121	<u>CN 1999-813686</u>	19991115
<u>TW 576835</u>	B	20040221	<u>TW 1999-88119810</u>	19991115
<u>AT 264858</u>	E	20040515	<u>AT 1999-958040</u>	19991115
<u>PT 1133496</u>	T	20040831	<u>PT 1999-958040</u>	19991115
<u>ES 2217843</u>	T3	20041101	<u>ES 1999-958040</u>	19991115
<u>RU 2247122</u>	C2	20050227	<u>RU 2001-117525</u>	19991115

<u>NO 2001002460</u>	A	20010518	<u>NO 2001-2460</u>	20010518
<u>US 6436955</u>	B1	20020820	<u>US 2001-856669</u>	20010523
<u>HK 1042703</u>	A1	20041203	<u>HK 2002-104444</u>	20020613
<u>PRIORITY APPLN. INFO.:</u>			<u>DE 1998-19854356</u>	A 19981125
			<u>WO 1999-EP8775</u>	W 19991115

GI



AB The title compd. in crystal modification A (I), useful as a medical and veterinary bactericide, is stable during extended storage without conversion to the amorphous form or any other crystal modification, and is less hygroscopic than the amorphous form of the compd. I is produced by dissolving the amorphous compd. or an unknown modification of it in hot water or a hot water-alc. mixt., adding an alc. (esp. EtOH or iso-PrOH), and cooling to room temp. I (m. 249-252°) is characterized by its powder x-ray diffractogram, differential thermogram, and IR spectrum.

IT 195532-12-8P


RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)

(crystal modification A of cyanocyclopropyl(diazabicyclononyl)fluorodihydrooxoquinolinecarboxylic acid)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full
Text

Citing
References

ACCESSION NUMBER: 2000:366035 HCAPLUS
DOCUMENT NUMBER: 133:4645
TITLE: Crystal modification B of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
INVENTOR(S): Himmler, Thomas; Hallenbach, Werner; Rast, Hubert
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX


DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>DE 19854355</u>	A1	20000531	<u>DE 1998-19854355</u>	19981125
<u>CA 2351707</u>	AA	20000602	<u>CA 1999-2351707</u>	19991115
<u>WO 2000031076</u>	A1	20000602	<u>WO 1999-EP8776</u>	19991115
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
<u>BR 9915682</u>	A	20010814	<u>BR 1999-15682</u>	19991115
<u>EP 1133497</u>	A1	20010919	<u>EP 1999-959278</u>	19991115
<u>EP 1133497</u>	B1	20050223		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
<u>TR 200101444</u>	T2	20020121	<u>TR 2001-200101444</u>	19991115
<u>JP 2002530407</u>	T2	20020917	<u>JP 2000-583904</u>	19991115
<u>NZ 511862</u>	A	20030829	<u>NZ 1999-511862</u>	19991115
<u>AU 767890</u>	B2	20031127	<u>AU 2000-16517</u>	19991115
<u>AT 289606</u>	E	20050315	<u>AT 1999-959278</u>	19991115
<u>RU 2248355</u>	C2	20050320	<u>RU 2001-117521</u>	19991115
<u>NO 2001002461</u>	A	20010518	<u>NO 2001-2461</u>	20010518
<u>US 6664268</u>	B1	20031216	<u>US 2001-856670</u>	20010523
<u>HK 1042705</u>	A1	20050311	<u>HK 2002-104458</u>	20020614

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): CASREACT 133:4645
 GI

<u>DE 1998-19854355</u>	A	19981125
<u>WO 1999-EP8776</u>	W	19991115



AB The title compd. in crystal modification B (I), useful as a medical and veterinary bactericide, is stable during extended storage without conversion to the amorphous form or any other crystal modification, and is less hygroscopic than the amorphous form of the compd. I is produced either (a) by reaction of 7-halo-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid with (1S,6S)-2,8-diazabicyclo[4.3.0]nonane in the presence of a base in a mixt. of EtOH and a polar aprotic diluent such as N-methylpyrrolidone, DMF, or sulfolane, or (b) by heating an unknown modification of the compd. in the presence of a base in EtOH, n-PrOH, iso-PrOH, or a mixt. of one of these alcs. with one of the polar aprotic diluents named previously. I (m. 243-245°) is characterized by its powder x-ray diffractogram, differential thermogram,

and IR spectrum.

IT **195532-12-8P**


RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)

(crystal modification B of cyanocyclopropyl(diazabicyclononyl)fluorodihydrooxoquinolinecarboxylic acid)

RN **195532-12-8** HCAPLUS

CN **3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-** (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text References

ACCESSION NUMBER: 1997:579724 HCAPLUS
DOCUMENT NUMBER: 127:248093
TITLE: 8-Cyano-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid derivatives
INVENTOR(S): Bartel, Stefan; Jaetsch, Thomas; Himmler, Thomas; Rast, Hans-Georg; Hallenbach, Werner; Heinen, Ernst; Pirro, Franz; Scheer, Martin; Stegemann, Michael; Stupp, Hans-Peter; Wetzstein, Heinz-Georg
PATENT ASSIGNEE(S): Bayer A.-G., Germany; Bartel, Stefan; Jaetsch, Thomas; Himmler, Thomas; Rast, Hans-Georg; Hallenbach, Werner; Heinen, Ernst; Pirro, Franz; Scheer, Martin; et al.
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 9731001</u>	A1	19970828	<u>WO 1997-EP637</u>	19970212
W: AU, BB, BG, BR, BY, CA, CN, CZ, HU, IL, JP, KR, KZ, LK, MX, NO, NZ, PL, RO, RU, SK, TR, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
<u>DE 19633805</u>	A1	19970828	<u>DE 1996-19633805</u>	19960822
<u>ZA 9701507</u>	A	19970916	<u>ZA 1997-1507</u>	19970202
<u>CA 2247020</u>	AA	19970828	<u>CA 1997-2247020</u>	19970212
<u>AU 9717689</u>	A1	19970910	<u>AU 1997-17689</u>	19970212
<u>AU 715341</u>	B2	20000120		
<u>EP 882049</u>	A1	19981209	<u>EP 1997-903260</u>	19970212
<u>EP 882049</u>	B1	20021120		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI			
<u>CN 1211984</u>	A	19990324	<u>CN 1997-192523</u> 19970212
<u>CN 1073112</u>	B	20011017	
<u>BR 9707606</u>	A	19990727	<u>BR 1997-7606</u> 19970212
<u>NZ 331468</u>	A	20000228	<u>NZ 1997-331468</u> 19970212
<u>JP 2000504734</u>	T2	20000418	<u>JP 1997-529755</u> 19970212
<u>IL 125444</u>	A1	20010319	<u>IL 1997-125444</u> 19970212
<u>RU 2173318</u>	C2	20010910	<u>RU 1998-117814</u> 19970212
<u>EP 1215202</u>	A1	20020619	<u>EP 2002-6519</u> 19970212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI			
<u>AT 228130</u>	E	20021215	<u>AT 1997-903260</u> 19970212
<u>CZ 291251</u>	B6	20030115	<u>CZ 1998-2684</u> 19970212
<u>ES 2184060</u>	T3	20030401	<u>ES 1997-903260</u> 19970212
<u>PT 882049</u>	T	20030430	<u>PT 1997-903260</u> 19970212
<u>PL 186737</u>	B1	20040227	<u>PL 1997-328577</u> 19970212
<u>TW 390879</u>	B	20000521	<u>TW 1997-86101994</u> 19970220
<u>US 6323213</u>	B1	20011127	<u>US 1998-125191</u> 19980813
<u>NO 9803819</u>	A	19980820	<u>NO 1998-3819</u> 19980820
<u>NO 311521</u>	B1	20011203	
<u>HK 1018903</u>	A1	20020510	<u>HK 1999-104030</u> 19990917
<u>US 6278013</u>	B1	20010821	<u>US 2000-718062</u> 20001121
<u>CN 1335301</u>	A	20020213	<u>CN 2001-110855</u> 20010228

PRIORITY APPLN. INFO.:

<u>DE 1996-19606762</u>	A	19960223
<u>DE 1996-19633805</u>	A	19960822
<u>EP 1997-903260</u>	A3	19970212
<u>WO 1997-EP637</u>	W	19970212
<u>US 1998-125191</u>	A3	19980813

OTHER SOURCE(S): MARPAT 127:248093
GI



AB Title compds. I [R1 = H, alkyl, optionally substituted by OH, OMe, NH2, NHMe, NMe2, or (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl; R2 = H, benzyl, alkyl, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, CH=CHCO2R3, CH2CH2CO2R3, CH2CH2CN, CH2CH2COMe, CH2COMe; R3 = Me, Et, R4(NHCHR5CO)n; R4 = H, alkyl, CO2CMe3; R5 = H, alkyl, hydroxyalkyl, aminoalkyl, thioalkyl, carboxyalkyl, benzyl; n = 1, 2; Y = O, S] were prepd. for use as antibacterial agents. Thus, I [R1 = OH, R2 = H, Y = O] was prepd. by aminating the 7-chloroquinoline. I [R1 = OH, R2 = H, Y = O] had min. inhibitory concns. against a no. of bacteria that were superior to those of enrofloxacin.

IT 195532-12-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of diazabicyclononylquinolinecarboxylic acid derivs. as bactericides)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 195532-14-0P 195532-16-2P 195532-18-4P
195532-20-8P 195532-22-0P 195532-25-3P
195532-27-5P 195532-29-7P 195532-31-1P
195532-33-3P 195532-36-6P 195532-39-9P
195532-42-4P 195532-45-7P 195532-48-0P
195532-58-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of diazabicyclononylquinolinecarboxylic acid derivs. as bactericides)

RN 195532-14-0 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 195532-16-2 HCAPLUS


CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 195532-12-8

CMF C21 H21 F N4 O3


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 195532-18-4 HCAPLUS


CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 195532-12-8

CMF C21 H21 F N4 O3


Absolute stereochemistry.



CM 2

CRN 104-15-4

CMF C7 H8 O3 S




RN 195532-20-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 195532-12-8
CMF C21 H21 F N4 O3

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 195532-22-0 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-7-[1-(3-ethoxy-3-oxo-1-propenyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-6-fluoro-1,4-dihydro-4-oxo-, [4aS-[1(E),4α,7α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 195532-25-3 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[octahydro-1-[(5-methyl-2-oxo-1,3-dioxolan-4-yl)methyl]-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, [4aS-(4α,7α)]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-27-5 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[octahydro-1-(3-oxobutyl)-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-29-7 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-7-[1-(2-cyanoethyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-31-1 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[octahydro-1-(2-oxopropyl)-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-33-3 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-7-[1-(3-ethoxy-3-oxopropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-6-fluoro-1,4-dihydro-4-oxo-, (4aS-cis)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-36-6 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-1-oxopropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4α,7α]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-39-9 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-1-oxopropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(S*),4α,7α]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-42-4 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-3-methyl-1-oxobutyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-45-7 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-1-oxo-3-phenylpropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-48-0 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-4-methyl-1-oxopentyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-58-2 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monosodium salt, (4aS-cis)-(9CI) (CA INDEX NAME).

Absolute stereochemistry.



=> s hamanaka, e?/au

L11 63 HAMANAKA, E?/AU

=> s hamanaka, e?/au

L12 63 HAMANAKA, E?/AU

=> s guzman-perez, a?/au

L13 18 GUZMAN-PEREZ, A?/AU

=> s mularski, c?/au

L14 10 MULARSKI, C?/AU

=> s ruggeri, r?/au

L15 141 RUGGERI, R?/AU

=> s wester, r?/au

L16 294 WESTER, R?/AU

=> s l11 and l13 and l14 and l15 and l16

L17 2 L11 AND L13 AND L14 AND L15 AND L16

=> d l17, ibib abs, 1-2

L17 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 2001:207067 HCAPLUS
 DOCUMENT NUMBER: 135:40413
 TITLE: Discovery of zoniporide: A potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility
 AUTHOR(S): **Guzman-Perez, A.; Wester, R. T.**; Allen, M. C.; Brown, J. A.; Buchholz, A. R.; Cook, E. R.; Day, W. W.; **Hamanaka, E. S.**; Kennedy, S. P.; Knight, D. R.; Kowalczyk, P. J.; Marala, R. B.; **Mularski, C. J.**; Novomisle, W. A.; **Ruggeri, R. B.**; Tracey, W. R.; Hill, R. J.
 CORPORATE SOURCE: Pfizer Global Research and Development, Pfizer Inc., Groton, CT, 06340, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(6), 803-807
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Zoniporide (CP-597,396) is a potent and selective inhibitor of NHE-1, which exhibits high aq. soly. and acceptable pharmacokinetics for i.v. administration. The discovery, synthesis, activities, and rat and dog pharmacokinetics of this compd. are presented. The potency and selectivity of zoniporide may be due to the conformation that the mol. adopts due to the presence of a cyclopropyl and a 5-quinolinyl substituent on the central pyrazole ring of the mol.
 REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 1999:566034 HCAPLUS
 DOCUMENT NUMBER: 131:199699
 TITLE: N-[(Substituted five-membered di- or triaza diunsaturated ring)carbonyl]guanidine derivatives for the treatment of ischemia
 INVENTOR(S): **Hamanaka, Ernest S.; Guzman-Perez, Angel; Ruggeri, Roger B.; Wester, Ronald T.; Mularski, Christian J.**
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 246 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 9943663</u>	A1	19990902	<u>WO 1999-IB206</u>	19990205
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,			

TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

<u>CA 2321642</u>	AA	19990902	<u>CA 1999-2321642</u>	19990205
<u>AU 9920706</u>	A1	19990915	<u>AU 1999-20706</u>	19990205
<u>AU 739403</u>	B2	20011011		
<u>BR 9908332</u>	A	20001107	<u>BR 1999-8332</u>	19990205
<u>EP 1056729</u>	A1	20001206	<u>EP 1999-901083</u>	19990205
<u>EP 1056729</u>	B1	20041229		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
SI, LT, LV, FI, RO

<u>TR 200002480</u>	T2	20001221	<u>TR 2000-200002480</u>	19990205
<u>JP 2002504546</u>	T2	20020212	<u>JP 2000-533420</u>	19990205
<u>EP 1454902</u>	A1	20040908	<u>EP 2004-8203</u>	19990205

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
SI, LT, LV, FI, RO, MK, CY, AL


<u>AT 286034</u>	E	20050115	<u>AT 1999-901083</u>	19990205
<u>ZA 9901578</u>	A	20000828	<u>ZA 1999-1578</u>	19990226
<u>US 6492401</u>	B1	20021210	<u>US 1999-367731</u>	19990818
<u>NO 2000004192</u>	A	20000822	<u>NO 2000-4192</u>	20000822
<u>HR 2000000550</u>	A1	20010228	<u>HR 2000-550</u>	20000824
<u>BG 104803</u>	A	20010531	<u>BG 2000-104803</u>	20000927
<u>HR 2001000666</u>	A1	20011031	<u>HR 2001-666</u>	20010829
<u>US 2003149043</u>	A1	20030807	<u>US 2002-315369</u>	20021209
<u>JP 2005041879</u>	A2	20050217	<u>JP 2004-248129</u>	20040827

PRIORITY APPLN. INFO.:

<u>US 1998-76362P</u>	P	19980227
<u>EP 1999-901083</u>	A3	19990205
<u>JP 2000-533420</u>	A3	19990205
<u>WO 1999-1B206</u>	W	19990205
<u>US 1999-367731</u>	A3	19990818

OTHER SOURCE(S): MARPAT 131:199699

GI



AB Guanidine derivs. ZCON:C(NH₂)₂ [I; Z = certain (un)substituted, diunsatd., diazoles and triazoles] and their pharmaceutically acceptable salts and/or prodrugs are disclosed, for use as inhibitors of sodium-hydrogen exchanger type 1 (NHE-1). Also disclosed are methods of using I, and pharmaceutical compns. contg. them. I are useful for the redn. of tissue damage resulting from tissue ischemia (no data). A large no. of compds. I and their intermediates were prepd. and/or specifically claimed. For instance, guanidine-HCl was converted to the free base, taken up in THF-DMF mixt., and coupled with 5-methyl-2-(2-methoxyphenyl)-2H-1,2,3-triazole-4-carboxylic acid (pre-activated with carbonyldiimidazole), and the resultant guanidine deriv. was isolated and acidified with HCl in MeOH, to give title compd. II.HCl in 17% yield.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:35:29 ON 10 MAY 2005)

FILE 'REGISTRY' ENTERED AT 15:36:23 ON 10 MAY 2005

L1 STRUCTURE UPLOADED
 L2 2 S L1
 L3 23 S L1 FULL
 L4 0 S L3 AND HAMANAKA, E?/AU

FILE 'HCAPLUS' ENTERED AT 15:40:40 ON 10 MAY 2005

L5 0 S L3 AND HAMANAKA, E?/AU
 L6 0 S L3 AND ANGEL, G?/AU
 L7 0 S L3 AND MULARSKI, C?/AU
 L8 0 S L3 AND RUGGERI, R?/AU
 L9 0 S L3 AND WESTER, R?/AU
 L10 13 S L3
 L11 63 S HAMANAKA, E?/AU
 L12 63 S HAMANAKA, E?/AU
 L13 18 S GUZMAN-PEREZ, A?/AU
 L14 10 S MULARSKI, C?/AU
 L15 141 S RUGGERI, R?/AU
 L16 294 S WESTER, R?/AU
 L17 2 S L11 AND L13 AND L14 AND L15 AND L16

=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	113.74	282.67
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-13.14	-13.14

FILE 'CAOLD' ENTERED AT 15:47:53 ON 10 MAY 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 15:35:29 ON 10 MAY 2005)

FILE 'REGISTRY' ENTERED AT 15:36:23 ON 10 MAY 2005

L1 STRUCTURE UPLOADED

L2 2 S L1
 L3 23 S L1 FULL
 L4 0 S L3 AND HAMANAKA, E?/AU

FILE 'HCAPLUS' ENTERED AT 15:40:40 ON 10 MAY 2005

L5 0 S L3 AND HAMANAKA, E?/AU
 L6 0 S L3 AND ANGEL, G?/AU
 L7 0 S L3 AND MULARSKI, C?/AU
 L8 0 S L3 AND RUGGERI, R?/AU
 L9 0 S L3 AND WESTER, R?/AU
 L10 13 S L3
 L11 63 S HAMANAKA, E?/AU
 L12 63 S HAMANAKA, E?/AU
 L13 18 S GUZMAN-PEREZ, A?/AU
 L14 10 S MULARSKI, C?/AU
 L15 141 S RUGGERI, R?/AU
 L16 294 S WESTER, R?/AU
 L17 2 S L11 AND L13 AND L14 AND L15 AND L16

FILE 'CAOLD' ENTERED AT 15:47:53 ON 10 MAY 2005

=> \$ 1.3

L18 0 L3

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	3.87	286.54
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-13.14

FILE 'REGISTRY' ENTERED AT 15:53:01 ON 10 MAY 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 MAY 2005 HIGHEST RN 850130-09-5

DICTIONARY FILE UPDATES: 9 MAY 2005 HIGHEST RN 850130-09-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

 *
 * The CA roles and document type information have been removed from *
 * the IDE default display format and the ED field has been added, *
 * effective March 20, 2005. A new display format, IDERL, is now *
 * available and contains the CA role and document type information. *
 *

Crossover limits have been increased. See [HELP CROSSOVER](#) for details.

Experimental and calculated property data are now available. For more information enter [HELP PROP](#) at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>


=>

L19 STRUCTURE UPLOADED

=> d 119

L19 HAS NO ANSWERS

L19 STR



NODE ATTRIBUTES:

HCOUNT	IS	M1	AT	8
NSPEC	IS	R	AT	1
NSPEC	IS	R	AT	2
NSPEC	IS	R	AT	3
NSPEC	IS	R	AT	4
NSPEC	IS	R	AT	5
NSPEC	IS	R	AT	6
NSPEC	IS	R	AT	7
NSPEC	IS	R	AT	8
NSPEC	IS	R	AT	9

DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE

=> s 119

SAMPLE SEARCH INITIATED 15:54:43 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 8004 TO ITERATE

12.5% PROCESSED 1000 ITERATIONS

1 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 154718 TO 165442

PROJECTED ANSWERS: 1 TO 329

L20 1 SEA SSS SAM L19

=> s l20 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 160.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 15:54:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 160147 TO ITERATE

100.0% PROCESSED 160147 ITERATIONS 198 ANSWERS
SEARCH TIME: 00.00.01

L21 198 SEA SSS FUL L19

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	162.19	448.73
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-13.14

FILE 'HCAPLUS' ENTERED AT 15:54:56 ON 10 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 May 2005 VOL 142 ISS 20
FILE LAST UPDATED: 9 May 2005 (20050509/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 15:35:29 ON 10 MAY 2005)

FILE 'REGISTRY' ENTERED AT 15:36:23 ON 10 MAY 2005

L1 STRUCTURE UPLOADED
L2 2 S L1
L3 23 S L1 FULL
L4 0 S L3 AND HAMANAKA, E?/AU

FILE 'HCAPLUS' ENTERED AT 15:40:40 ON 10 MAY 2005

L5 0 S L3 AND HAMANAKA, E?/AU
L6 0 S L3 AND ANGEL, G?/AU
L7 0 S L3 AND MULARSKI, C?/AU
L8 0 S L3 AND RUGGERI, R?/AU

L9 0 S L3 AND WESTER, R?/AU
 L10 13 S L3
 L11 63 S HAMANAKA, E?/AU
 L12 63 S HAMANAKA, E?/AU
 L13 18 S GUZMAN-PEREZ, A?/AU
 L14 10 S MULARSKI, C?/AU
 L15 141 S RUGGERI, R?/AU
 L16 294 S WESTER, R?/AU
 L17 2 S L11 AND L13 AND L14 AND L15 AND L16

FILE 'CAOLD' ENTERED AT 15:47:53 ON 10 MAY 2005
 L18 0 S L3

FILE 'REGISTRY' ENTERED AT 15:53:01 ON 10 MAY 2005
 L19 STRUCTURE UPLOADED
 L20 1 S L19
 L21 198 S L20 FULL

FILE 'HCAPLUS' ENTERED AT 15:54:56 ON 10 MAY 2005

=> s l21/rct
 197 L21
 2729491 RCT/RL
 L22 118 L21/RCT
 (L21 (L) RCT/RL)

=> s l3/prep
 13 L3
 3300320 PREP/RL
 L23 4 L3/PREP
 (L3 (L) PREP/RL)

=> s l23 and l22
 L24 3 L23 AND L22

=> d l24, ibib abs hitstr, 1-3

L24 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text	Citing References
ACCESSION NUMBER:	2000:366037 HCAPLUS
DOCUMENT NUMBER:	133:4647
TITLE:	Semihydrochloride of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
INVENTOR(S):	Himmeler, Thomas; Rast, Hubert
PATENT ASSIGNEE(S):	Bayer A.-G., Germany
SOURCE:	Ger. Offen., 16 pp. CODEN: GWXXBX
DOCUMENT TYPE:	Patent
LANGUAGE:	German
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>DE 19854357</u>	A1	20000531	<u>DE 1998-19854357</u>	19981125
<u>CA 2351714</u>	AA	20000602	<u>CA 1999-2351714</u>	19991115
<u>WO 2000031077</u>	A1	20000602	<u>WO 1999-EP8778</u>	19991115
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				

CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
 IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
 MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

<u>BR 9915684</u>	A	20010814	<u>BR 1999-15684</u>	19991115
<u>EP 1133495</u>	A1	20010919	<u>EP 1999-955995</u>	19991115
<u>EP 1133495</u>	B1	20021009		


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO

<u>TR 200101443</u>	T2	20010921	<u>TR 2001-200101443</u>	19991115
<u>JP 2002530408</u>	T2	20020917	<u>JP 2000-583905</u>	19991115
<u>AT 225790</u>	E	20021015	<u>AT 1999-955995</u>	19991115
<u>ES 2181488</u>	T3	20030216	<u>ES 1999-955995</u>	19991115
<u>PT 1133495</u>	T	20030228	<u>PT 1999-955995</u>	19991115
<u>AU 759769</u>	B2	20030501	<u>AU 2000-12716</u>	19991115
<u>NZ 511863</u>	A	20030530	<u>NZ 1999-511863</u>	19991115
<u>RU 2242475</u>	C2	20041220	<u>RU 2001-117528</u>	19991115
<u>NO 2001002532</u>	A	20010702	<u>NO 2001-2532</u>	20010523

PRIORITY APPLN. INFO.:

<u>DE 1998-19854357</u>	A	19981125
<u>WO 1999-EP8778</u>	W	19991115

OTHER SOURCE(S): CASREACT 133:4647
 GI



AB The title compd. (I), useful as a medical and veterinary bactericide, shows good water soly. (19 wt.%). I is produced by reaction of 7-halo-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid with (1S,6S)-2,8-diazabicyclo[4.3.0]nonane in the presence of a base in one of the following diluents: (a) a C₂+4 aliph. alc., (b) a mixt. of a C₃+3 alc. with the polar aprotic diluent, N-methylpyrrolidone; (c) a mixt. of n-PrOH with DMF. I (m. 278-280°) is characterized by its powder x-ray diffractogram, differential thermogram, and IR spectrum.


IT 271252-05-2P

RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); **PREP (Preparation)**; PROC (Process)
 (semihydrochloride of cyanocyclopropyl(diazabicyclononyl)fluorodihydroxoquinolinecarboxylic acid)

RN 271252-05-2 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride (2:1) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


IT 151213-40-0RL: **RCT (Reactant)**; RACT (Reactant or reagent)

(semihydrochloride of cyanocyclopropyl (diazabicyclononyl) fluorodihydrooxoquinolinecarboxylic acid)

RN 151213-40-0 HCAPLUS

CN 1H-Pyrrolo[3,4-b]pyridine, octahydro-, (4aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L24 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text	Chemical References
--------------	------------------------

ACCESSION NUMBER: 2000:366035 HCAPLUS

DOCUMENT NUMBER: 133:4645

TITLE: Crystal modification B of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

INVENTOR(S): Himmeler, Thomas; Hallenbach, Werner; Rast, Hubert

PATENT ASSIGNEE(S): Bayer A.-G., Germany

SOURCE: Ger. Offen., 8 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>DE 19854355</u>	A1	20000531	<u>DE 1998-19854355</u>	19981125
<u>CA 2351707</u>	AA	20000602	<u>CA 1999-2351707</u>	19991115
<u>WO 2000031076</u>	A1	20000602	<u>WO 1999-EP8776</u>	19991115


W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

<u>BR 9915682</u>	A	20010814	<u>BR 1999-15682</u>	19991115
<u>EP 1133497</u>	A1	20010919	<u>EP 1999-959278</u>	19991115
<u>EP 1133497</u>	B1	20050223		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
<u>TR 200101444</u>	T2	20020121	<u>TR 2001-200101444</u>	19991115
<u>JP 2002530407</u>	T2	20020917	<u>JP 2000-583904</u>	19991115
<u>NZ 511862</u>	A	20030829	<u>NZ 1999-511862</u>	19991115
<u>AU 767890</u>	B2	20031127	<u>AU 2000-16517</u>	19991115
<u>AT 289606</u>	E	20050315	<u>AT 1999-959278</u>	19991115
<u>RU 2248355</u>	C2	20050320	<u>RU 2001-117521</u>	19991115
<u>NO 2001002461</u>	A	20010518	<u>NO 2001-2461</u>	20010518
<u>US 6664268</u>	B1	20031216	<u>US 2001-856670</u>	20010523
<u>HK 1042705</u>	A1	20050311	<u>HK 2002-104458</u>	20020614

PRIORITY APPLN. INFO.:

<u>DE 1998-19854355</u>	A	19981125
<u>WO 1999-EP8776</u>	W	19991115

OTHER SOURCE(S): CASREACT 133:4645
GI

AB The title compd. in crystal modification B (I), useful as a medical and veterinary bactericide, is stable during extended storage without conversion to the amorphous form or any other crystal modification, and is less hygroscopic than the amorphous form of the compd. I is produced either (a) by reaction of 7-halo-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid with (1S,6S)-2,8-diazabicyclo[4.3.0]nonane in the presence of a base in a mixt. of EtOH and a polar aprotic diluent such as N-methylpyrrolidone, DMF, or sulfolane, or (b) by heating an unknown modification of the compd. in the presence of a base in EtOH, n-PrOH, iso-PrOH, or a mixt. of one of these alcs. with one of the polar aprotic diluents named previously. I (m. 243-245°) is characterized by its powder x-ray diffractogram, differential thermogram, and IR spectrum.


IT **195532-12-8P**

RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); **PREP (Preparation)**; PROC (Process)
(crystal modification B of cyanocyclopropyl(diazabicyclononyl)fluorodihydrooxoquinolinecarboxylic acid)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


IT 151213-40-0RL: **RCT (Reactant)**; RACT (Reactant or reagent)

(crystal modification B of cyanocyclopropyl(diazabicyclononyl)fluorodihydrooxoquinolinecarboxylic acid)

RN 151213-40-0 HCAPLUS

CN 1H-Pyrrolo[3,4-b]pyridine, octahydro-, (4aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L24 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 1997:579724 HCAPLUS
 DOCUMENT NUMBER: 127:248093
 TITLE: 8-Cyano-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid derivatives
 INVENTOR(S): Bartel, Stefan; Jaetsch, Thomas; Himmler, Thomas; Rast, Hans-Georg; Hallenbach, Werner; Heinen, Ernst; Pirro, Franz; Scheer, Martin; Stegemann, Michael; Stupp, Hans-Peter; Wetzstein, Heinz-Georg
 PATENT ASSIGNEE(S): Bayer A.-G., Germany; Bartel, Stefan; Jaetsch, Thomas; Himmler, Thomas; Rast, Hans-Georg; Hallenbach, Werner; Heinen, Ernst; Pirro, Franz; Scheer, Martin; et al.
 SOURCE: PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 9731001</u>	A1	19970828	<u>WO 1997-EP637</u>	19970212
W: AU, BB, BG, BR, BY, CA, CN, CZ, NZ, PL, RO, RU, SK, TR, UA, US			HU, IL, JP, KR, KZ, LK, MX, NO,	
RW: AT, BE, CH, DE, DK, ES, FI, FR, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			GB, GR, IE, IT, LU, MC, NL, PT,	
<u>DE 19633805</u>	A1	19970828	<u>DE 1996-19633805</u>	19960822
<u>ZA 9701507</u>	A	19970916	<u>ZA 1997-1507</u>	19970202
<u>CA 2247020</u>	AA	19970828	<u>CA 1997-2247020</u>	19970212
<u>AU 9717689</u>	A1	19970910	<u>AU 1997-17689</u>	19970212
<u>AU 715341</u>	B2	20000120		

EP 882049	A1	19981209	EP 1997-903260	19970212
EP 882049	B1	20021120		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
CN 1211984	A	19990324	CN 1997-192523	19970212
CN 1073112	B	20011017		
BR 9707606	A	19990727	BR 1997-7606	19970212
NZ 331468	A	20000228	NZ 1997-331468	19970212
JP 2000504734	T2	20000418	JP 1997-529755	19970212
IL 125444	A1	20010319	IL 1997-125444	19970212
RU 2173318	C2	20010910	RU 1998-117814	19970212
EP 1215202	A1	20020619	EP 2002-6519	19970212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
AT 228130	E	20021215	AT 1997-903260	19970212
CZ 291251	B6	20030115	CZ 1998-2684	19970212
ES 2184060	T3	20030401	ES 1997-903260	19970212
PT 882049	T	20030430	PT 1997-903260	19970212
PL 186737	B1	20040227	PL 1997-328577	19970212
TW 390879	B	20000521	TW 1997-86101994	19970220
US 6323213	B1	20011127	US 1998-125191	19980813
NO 9803819	A	19980820	NO 1998-3819	19980820
NO 311521	B1	20011203		
HK 1018903	A1	20020510	HK 1999-104030	19990917
US 6278013	B1	20010821	US 2000-718062	20001121
CN 1335301	A	20020213	CN 2001-110855	20010228

PRIORITY APPLN. INFO.:

DE 1996-19606762	A	19960223
DE 1996-19633805	A	19960822
EP 1997-903260	A3	19970212
WO 1997-EP637	W	19970212
US 1998-125191	A3	19980813

OTHER SOURCE(S): MARPAT 127:248093
GI



AB Title compds. I [R1 = H, alkyl, optionally substituted by OH, OMe, NH2, NHMe, NMe2, or (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl; R2 = H, benzyl, alkyl, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, CH=CHCO2R3, CH2CH2CO2R3, CH2CH2CN, CH2CH2COMe, CH2COMe; R3 = Me, Et, R4(NHCHR5CO)n; R4 = H, alkyl, CO2CMe3; R5 = H, alkyl, hydroxyalkyl, aminoalkyl, thioalkyl, carboxyalkyl, benzyl; n = 1, 2; Y = O, S] were prepd. for use as antibacterial agents. Thus, I [R1 = OH, R2 = H, Y = O] was prepd. by aminating the 7-chloroquinoline. I [R1 = OH, R2 = H, Y = O] had min. inhibitory concns. against a no. of bacteria that were superior to those of enrofloxacin.

IT 195532-12-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)


(prepn. of diazabicyclononylquinolinecarboxylic acid derivs. as bactericides)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-

[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 151213-40-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of diazabicyclononylquinolinecarboxylic acid derivs. as bactericides)

RN 151213-40-0 HCAPLUS

CN 1H-Pyrrolo[3,4-b]pyridine, octahydro-, (4aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 195532-14-0P 195532-16-2P 195532-18-4P

195532-20-8P 195532-22-0P 195532-25-3P

195532-27-5P 195532-29-7P 195532-31-1P

195532-33-3P 195532-36-6P 195532-39-9P

195532-42-4P 195532-45-7P 195532-48-0P


195532-58-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diazabicyclononylquinolinecarboxylic acid derivs. as bactericides)

RN 195532-14-0 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




HCl

RN 195532-16-2 HCAPLUS
 CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 195532-12-8
 CMF C21 H21 F N4 O3

Absolute stereochemistry.



CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 195532-18-4 HCAPLUS
 CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1


CRN 195532-12-8
 CMF C21 H21 F N4 O3

Absolute stereochemistry.



CM 2

CRN 104-15-4
 CMF C7 H8 O3 S



RN 195532-20-8 HCAPLUS


CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 195532-12-8

CMF C21 H21 F N4 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 195532-22-0 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-7-[1-(3-ethoxy-3-oxo-1-propenyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-6-fluoro-1,4-dihydro-4-oxo-, [4aS-[1(E),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 195532-25-3 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-

[octahydro-1-[(5-methyl-2-oxo-1,3-dioxolan-4-yl)methyl]-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, [4aS-(4a α ,7a α)]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-27-5 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-
[octahydro-1-(3-oxobutyl)-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-,
(4aS-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-29-7 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-7-[1-(2-cyanoethyl)octahydro-6H-
pyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-,
(4aS-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-31-1 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-
[octahydro-1-(2-oxopropyl)-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-,
(4aS-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-33-3 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-7-[1-(3-ethoxy-3-oxopropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-6-fluoro-1,4-dihydro-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-36-6 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-1-oxopropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




HCl

RN 195532-39-9 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-1-oxopropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(S*),4aα,7aα]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-42-4 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-3-methyl-1-oxobutyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-45-7 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-1-oxo-3-phenylpropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-48-0 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-4-methyl-1-oxopentyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195532-58-2 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monosodium salt, (4aS-cis)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 15:35:29 ON 10 MAY 2005)

FILE 'REGISTRY' ENTERED AT 15:36:23 ON 10 MAY 2005

L1 STRUCTURE UPLOADED
 L2 2 S L1
 L3 23 S L1 FULL
 L4 0 S L3 AND HAMANAKA, E?/AU

FILE 'HCAPLUS' ENTERED AT 15:40:40 ON 10 MAY 2005

L5 0 S L3 AND HAMANAKA, E?/AU
 L6 0 S L3 AND ANGEL, G?/AU
 L7 0 S L3 AND MULARSKI, C?/AU
 L8 0 S L3 AND RUGGERI, R?/AU
 L9 0 S L3 AND WESTER, R?/AU
 L10 13 S L3
 L11 63 S HAMANAKA, E?/AU
 L12 63 S HAMANAKA, E?/AU
 L13 18 S GUZMAN-PEREZ, A?/AU
 L14 10 S MULARSKI, C?/AU
 L15 141 S RUGGERI, R?/AU

L16 294 S WESTER, R?/AU
L17 2 S L11 AND L13 AND L14 AND L15 AND L16

FILE 'CAOLD' ENTERED AT 15:47:53 ON 10 MAY 2005
L18 0 S L3

FILE 'REGISTRY' ENTERED AT 15:53:01 ON 10 MAY 2005
L19 STRUCTURE UPLOADED
L20 1 S L19
L21 198 S L20 FULL

FILE 'HCAPLUS' ENTERED AT 15:54:56 ON 10 MAY 2005
L22 118 S L21/RCT
L23 4 S L3/PREP
L24 3 S L23 AND L22

=>